Shuttle Pharmaceuticals Inc (SHPH)
Shuttle Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies. Its pipeline includes Ropidoxuridine, an oral halogenated pyrimidine being studied for brain tumors and sarcomas, along with several earlier-stage programs such as SP-2-225, SP-1-303, and SP-1-161. These candidates are being evaluated across different oncology-related and immune or epigenetic pathways, including treatment approaches for ER-positive breast cancer and other malignancies. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland. Shuttle Pharmaceuticals Inc. common stock is listed on the NASDAQ under the symbol SHPH.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SHPH
|
$3.55
|
9.6% Upside
|
Fair
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-0.2x
|
0.6x
|
—
|
1.773 M
|
1.058 M
|
10.9%
|
99.5%
|
-43.5
|
—
|
86.6%
|
